Literature DB >> 31792926

Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study.

María J Cejalvo1, Mario Legarda1, Eugenia Abella2, Elena Cabezudo3, Cristina Encinas4, Ana García-Feria5, Mercedes Gironella6, Belén Iñigo7, Jesús Martín8, Paz Ribas1, Mª Ángeles Ruíz9, Yolanda González10, Isabel Vicuña11, Ángel Ramírez12, Pascual Fernández13, Javier de la Rubia1,14.   

Abstract

Entities:  

Keywords:  daratumumab; dialysis; multiple myeloma; relapse

Year:  2019        PMID： 31792926     DOI： 10.1111/bjh.16286

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen.

Authors:  Shinichi Mizuno; Chigusa Kitayama; Kenta Yamaguchi; Satoru Sanada; Toshinobu Sato
Journal:  Int J Hematol       Date:  2020-07-24       Impact factor: 2.490

2.  Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.

Authors:  Shinichi Mizuno; Chigusa Kitayama; Shigeto Mashiko; Satoru Sanada
Journal:  CEN Case Rep       Date:  2021-11-24

Review 3.  An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.

Authors:  Meletios A Dimopoulos; Joseph Mikhael; Evangelos Terpos; Xavier Leleu; Philippe Moreau; Joan Bladé; Jin Seok Kim; Keith Stockerl-Goldstein; Paul G Richardson
Journal:  Ther Adv Hematol       Date:  2022-04-02

4.  Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.

Authors:  Marcelo Capra; Thomas Martin; Philippe Moreau; Ross Baker; Ludek Pour; Chang-Ki Min; Xavier Leleu; Mohamad Mohty; Marta Reinoso Segura; Mehmet Turgut; Richard LeBlanc; Marie-Laure Risse; Laure Malinge; Sandrine Schwab; Meletios Dimopoulos
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

Review 5.  Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma.

Authors:  Anusha Bapatla; Arunima Kaul; Paramvijay Singh Dhalla; Ana S Armenta-Quiroga; Raheela Khalid; Jian Garcia; Safeera Khan
Journal:  Cureus       Date:  2021-06-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.